Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, ...

Amgen Inc.'s stock has surged 13% recently, likely due to promising developments with its obesity injection, MariTide, which offers unique benefits over current treatments. MariTide's dual ...

Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly launched trials. Historically, the California-based pharma has remained ...

Amgen shareholders are celebrating ... There is also anticipation building for MariTide, its experimental obesity drug entering phase 3 trials, which could position the company to enter the ...